Company / R&D Expense
BioAge Labs, Inc. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$74.0M
FY2025
5-year range
$33.9M / $74.0M
FY2023-FY2025
Trend
+25.3%
vs FY2024
Sector context
#163 of 210
Health Care
What the data says
BioAge Labs, Inc.'s r&d expense of $74M is lower than 78% of companies in the Health Care sector (FY2025). Improved from $34M to $74M over the past 2 years.
Based on SEC 10-K filings.
$74M in FY2025.
Improved from $34M to $74M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 210This company $74.0M Sector average $644.1M
▼
-88.5% below sector average
Key checks
Key Insights
- In FY2025, r&d expense increased 25.3% year-over-year.
- Ranks #163 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.75 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $74.0M | +25.3% |
| FY2024 | $59.0M | +74.2% |
| FY2023 | $33.9M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026